INFLUENCE OF THE AGE OF THE DIAGNOSIS AND THE BEGINNING OF SPECIFIC THERAPY ON MAIN CLINICAL AND LABORATORY MANIFESTATIONS OF A DISEASE IN PATIENTS WITH CYSTIC FIBROSIS
https://doi.org/10.15690/vsp.v13i2.971
Abstract
Background: To establish features of a clinical course of a disease at patients depending on age of firstly determine diagnosis of cystic fibrosis. Patients and methods: We examined 130 patients with cystic fibrosis aged under 25 years old. Depending on the age of diagnosis 3 groups of patients were formed: diagnosed at the age of 0–7, 8–18 and 18–25 years old. Results: There were no differences in the main anthropometric, functional, microbiological characteristics and frequency of complications at the age of 25 years between the patients of all three groups. However significant differences in «severity» of genotypes are defined: in group with the diagnosis established at preschool age, «severe» genotypes dominated, in group with the diagnosis established in 7–18 and 18–25 years, — «mild» genotypes. Importance of treatment with dornase alfa in all patients with cystic fibrosis regarding age of establishment of the diagnosis was shown. Conclusion: Early diagnostics determines appropriate beginning of the treatment, which can improve the further prognosis of the disease course. However late diagnostics in patients with «mild» genotype does not have significant influence on the clinical course at the age of 25 years old, which proves protective effects of «mild» mutations.
About the Authors
S. A. Krasovskii
Scientific Research Institute of Pulmonology, Moscow
Russian Federation
Stanislav Krasovskiy, Candidate of Medical Science, research scientist of the mucoviscidosis laboratory
Russian Federation
Stanislav Krasovskiy, Candidate of Medical Science, research scientist of the mucoviscidosis laboratory
N. Yu. Kashirskaya
Research Centre of Medical Genetics, Moscow
Russian Federation
Russian Federation
M. V. Usacheva
Scientific Research Institute of Pulmonology, Moscow
Russian Federation
Russian Federation
E. L. Amelina
Scientific Research Institute of Pulmonology, Moscow
Russian Federation
Russian Federation
A. V. Chernyak
Scientific Research Institute of Pulmonology, Moscow
Russian Federation
Russian Federation
Zh.K. Naumenko
Scientific Research Institute of Pulmonology, Moscow
Russian Federation
Russian Federation
References
1. Mukovistsidoz. Sovremennyye dostizheniya i aktual'nyye problemy. Metodicheskiye rekomendatsii [Mucoviscidosis. Modern Achievements and Actual Problems. Methodical Recommendations]. The 4th ed., rev. and enl. Ed. Kapranov N. I., Kashirskaya N.Yu. М.: 4ТЕ Аrt. 2011. 124 p.
2. Krasovskiy S. A. Osteoporoz u vzroslykh bol'nykh mukovistsidozom [Osteoporosis in Adult Cystic Fibrosis Patients]. Synopsis of thesis for the degree of Candidate of Medical Science. М. 2012. 26 p.
3. Schechter M. Variability of clinical course in cystic fibrosis. In: Cystic fibrosis. Third edn. M. Hodson, G. Duncan, A. Bush (eds). London: Edward Arnold (Publishers) Ltd. 2007. P. 87–95.
4. Doull I.J.M., Ryley H. C., Weller P. Cystic fibrosis-related deaths in infancy and the effect of newborn screening. Pediatr. Pulmonol. 2001; 31: 363–366.
5. Cystic Fibrosis Foundation, Patient Registry 2012 Annual Report, Cystic Fibrosis Foundation. Bethesda, Md, USA. 2013. www.cff.org
6. Krasovskiy S. A., Amelina Ye. L., Chernyak A. V., Nikonova V. S., Voronkova A.Yu., Kashirskaya N.Yu., Kapranov N. I., Chistyakova V. P., Samoylenko V. A., Semykin S.Yu., Simonova O. I., Petrova N. V., Gorinova Yu. V., Chuchalin A. G. Terapevticheskii Arkhiv — Therapeutic Archive. 2012; 3: 54–58.
7. Doring G., Hoiby N. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. For the Consensus Study Group. J. Cyst. Fibros. 2004; 3: 67–91. 8
8. . Farrell P., Shen G., Koscik R. E., Bruns W. T., Splaingard M., Mischler E. H. Nutritional benefits of neonatal screening for cystic fibrosis. N. Engl. J. Med. 1997; 337: 963–969.
9. Farrell P. M., Kosorok M. R., Rock M. J., Laxova A., Zeng L., Lai H. C., Hoffman G., Laessig R. H., Splaingard M. L. Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. Pediatrics. 2001; 107: 1–13.
10. Krasovskiy S. A. Nikonova V. S., Kashirskaya N.Yu., Kondrat'yeva Ye. I., Chernyak A. V., Kapranov N. I., Amelina Ye. L., Sherman V. D., Samoylenko V. A., Voronkova A.Yu., Shabalova L. A., Simonova O. I., Usacheva M. V., Chernikov V. V. Voprosi sovremennoi pediatrii — Current Pediatrics. 2013; 12 (1): 17–23.
11. Dijk F. N., McKay K., Barzi F., Gaskin K. J., Fitzgerald D. A. Improved survival in cystic fibrosis patients diagnosed by newborn screening compared to a historical cohort from the same centre. Arch. Dis. Child. 2011; 96 (12): 1118–1123.
12. Conway S. P., Brownlee K. G., Peckman D. G. Cystic fibrosis in children and adults. The Leeds method of management. Revised edn., number 7. St. James and Seacroft University Hospitals. Leeds Teaching Hospital Trust, Beckettstreet, Leeds, UK. 2008. P. 130–141.
13. Сastellani С., Cuppens H., Macek Jr., Cassiman J. J., Kerem E., Durie P., Tullis E., Assael B. M., Bombieri C., Brown A., Casals T., Claustres M., Cutting G. R., Dequeker E., Dodge J., Doull I., Farrell P., Ferec C., Girodon E., Johannesson M., Kerem B., Knowles M., Munck A., Pignatti P. F., Radojkovic D., Rizzotti P., Schwarz M., Stuhrmann M., Tzetis M., Zielenski J., Elborn J. S. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. J. Cyst. Fibros. 2008; 7: 179–186.
14. Krasovskiy S. A., Amelina Ye. L., Chernyak A. V., Kashirskaya N. Yu., Nikonova V. S., Voronkova A.Yu., Kondrat'yeva Ye. I., Samoylenko V. A., Sherman V. D., Kapranov N. I., Usacheva M. V., Naumenko Zh. K., Gorinova Yu. V., Chuchalin A. G. Pul'monologija — Pulmonology. 2013; 2: 27–32.
15. Krasovskiy S. A., Petrova N. V., Stepanova A. A., Usacheva M. V., Samoylenko V. A., Amelina Ye. L., Nikonova V. S. Pul'monologija — Pulmonology. 2012; 6: 5–11.
16. Debray D., Kelly D., Houwen R., Strandvik B., Strandvik B., Colombo C. Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease. J. Cyst. Fibros. 2011; 10 (Suppl. 2): 29–36.
17. Boyce J. M., Pittet D. Guideline for Hand Hygiene in Health-Care Settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Society for Healthcare Epidemiology of America/Association for Professionals in Infection Control/Infectious Diseases Society of America. MMWR Recomm. Rep. 2002; 51: 1–45.
18. Quan J. M., Tiddens H. A. W.M., Sy J. P., McKenzie S. G., Montgomery M. D., Robinson P. J., Wohl M. E., Konstan M. W. A two-year randomized, placebo-controlled trial of dornasealfa in patients with cystic fibrosis and mild lung function abnormalities. J. Pediatr. 2001; 139: 813–820.
19. Shah P. L., Conway S., Scott S. F., Rainisio M., Wildman M., Stableforth D., Hodson M. E. A case-controlled study with dornase alfa to evaluate impact on disease progression over a 4 year period. Respiration. 2001; 68: 160–164.
20. Hodson M. E., McKenzie S., Нarms H. K., Koch C., Mastella G., Navarro J., Strandvik B. Dornase alfa in the treatment of cystic fibrosis in Europe: a report from the epidemiologic registry of cystic fibrosis. Pediatr. Pulmonol. 2003; 36 (5): 427–432.
21. Hodson M. E., Shah P. L. DNase trials in cystic fibrosis. Eur. Respir. J. 1995; 8: 1786–1791.
22. Нarms H. K., Matouk E., Tournier G., von der Hardt H., Weller P. H., Romano L., Heijerman H. G., FitzGerald M. X., Richard D., Strandvik B., Kolbe J., Kraemer R., Michalsen H. Multicenter, open-label study of recombinant human DNase in cystic fibrosis patients with moderate lung disease. Pediatr. Pulmonol. 1998; 26: 155–161.
23. Shah P. L., Bush A., Canny G. J., Colin A. A., Fuchs H. J., Geddes D. M., Johnson C. A.C., Light M. C., Scott S. F., Tullis D. E., De Vault A., Wohl M. E., Hodson M. E. Recombinant human DNase I in cystic fibrosis patients with severe pulmonary disease: A short-term, double-blind study followed by six months open-label treatment. Eur. Respir. J. 1995; 8: 954–958.
24. McKenzie S. G., Chowdhury S., Strandvik B., Hodson M. E. Dornase-alfa is well tolerated: data from the epidemiologic registry of cystic fibrosis. Pediatr. Pulmonol. 2007; 42 (10): 928–937.
25. George P. M., Bilton D., Hodson M. E., Bilton D., Cullinan P., Hodson M. E., Simmonds N. J. Improved survival at low lung function in cystic fibrosis: cohort study from 1990 to 2007. BMJ. 2011; 342: 1008.
Review
For citations:
Krasovskii S.A., Kashirskaya N.Yu., Usacheva M.V., Amelina E.L., Chernyak A.V., Naumenko Zh. INFLUENCE OF THE AGE OF THE DIAGNOSIS AND THE BEGINNING OF SPECIFIC THERAPY ON MAIN CLINICAL AND LABORATORY MANIFESTATIONS OF A DISEASE IN PATIENTS WITH CYSTIC FIBROSIS. Current Pediatrics. 2014;13(2):36-43. (In Russ.) https://doi.org/10.15690/vsp.v13i2.971
Views:
1172
Email this article 
